Zucchetto Antonella, Sonego Paolo, Degan Massimo, Bomben Riccardo, Dal Bo Michele, Bulian Pietro, Benedetti Dania, Rupolo Maurizio, Del Poeta Giovanni, Campanini Renato, Gattei Valter
Clinical and Experimental Hematology Research Unit, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano (PN), Italy.
J Transl Med. 2006 Mar 1;4:11. doi: 10.1186/1479-5876-4-11.
Studies of gene expression profiling have been successfully used for the identification of molecules to be employed as potential prognosticators. In analogy with gene expression profiling, we have recently proposed a novel method to identify the immunophenotypic signature of B-cell chronic lymphocytic leukemia subsets with different prognosis, named surface-antigen expression profiling. According to this approach, surface marker expression data can be analysed by data mining tools identical to those employed in gene expression profiling studies, including unsupervised and supervised algorithms, with the aim of identifying the immunophenotypic signature of B-cell chronic lymphocytic leukemia subsets with different prognosis. Here we provide an overview of the overall strategy employed for the development of such an "outcome class-predictor" based on surface-antigen expression signatures. In addition, we will also discuss how to transfer the obtained information into the routine clinical practice by providing a flow-chart indicating how to select the most relevant antigens and build-up a prognostic scoring system by weighing each antigen according to its predictive power. Although referred to B-cell chronic lymphocytic leukemia, the methodology discussed here can be also useful in the study of diseases other than B-cell chronic lymphocytic leukemia, when the purpose is to identify novel prognostic determinants.
基因表达谱研究已成功用于识别可作为潜在预后指标的分子。与基因表达谱类似,我们最近提出了一种新方法,用于识别具有不同预后的B细胞慢性淋巴细胞白血病亚群的免疫表型特征,称为表面抗原表达谱。根据这种方法,可以使用与基因表达谱研究中相同的数据挖掘工具来分析表面标志物表达数据,包括无监督和有监督算法,目的是识别具有不同预后的B细胞慢性淋巴细胞白血病亚群的免疫表型特征。在此,我们概述了基于表面抗原表达特征开发这种“结果类别预测器”所采用的总体策略。此外,我们还将讨论如何通过提供一个流程图,说明如何选择最相关的抗原,并根据每个抗原的预测能力对其进行加权,从而构建一个预后评分系统,将获得的信息转化为常规临床实践。虽然这里提到的是B细胞慢性淋巴细胞白血病,但当目的是识别新的预后决定因素时,这里讨论的方法在研究除B细胞慢性淋巴细胞白血病以外的其他疾病时也可能有用。